8-K/AAcquisitions & DispositionsExhibits & Filings

JOHNSON & JOHNSON 8-K/A Report, Acquisition Completed (Mar 2, 2007)

Filed March 2, 2007For Securities:JNJ

Summary

This Form 8-K/A filing by Johnson & Johnson (JNJ) serves as an amendment to a previous filing on December 21, 2006, to include crucial financial information related to the acquisition of Pfizer Inc.'s Consumer Healthcare business. The acquisition, completed on December 20, 2006, was for a substantial $16.6 billion in cash. This amendment is critical for investors as it provides the necessary financial statements to understand the impact of this significant acquisition. It includes audited combined financial statements for the Pfizer Consumer Healthcare business for the years 2005 and 2004, and unaudited statements for the nine months ending in 2006 and 2005. Additionally, pro forma financial information for Johnson & Johnson, reflecting the combined entity, for fiscal years 2006 and 2006, is also provided.

Key Highlights

  • 1Johnson & Johnson (JNJ) filed an 8-K/A on March 2, 2007, to amend a prior filing regarding the acquisition of Pfizer's Consumer Healthcare business.
  • 2The acquisition of Pfizer Consumer Healthcare was completed on December 20, 2006, for $16.6 billion in cash.
  • 3This amendment provides key financial statements for the acquired Pfizer Consumer Healthcare business, including audited data for FY2005 and FY2004.
  • 4Unaudited financial statements for the nine-month periods ending October 1, 2006, and October 2, 2005, for Pfizer Consumer Healthcare are also included.
  • 5The filing includes unaudited condensed combined pro forma financial information for Johnson & Johnson and its subsidiaries for the fiscal years ended December 31, 2006, and January 1, 2006.
  • 6The purpose of the amendment is to furnish financial information that was unavailable at the time of the original Form 8-K filing.

Frequently Asked Questions

The main purpose of this Form 8-K/A filing is to provide essential financial statements and pro forma information that were not available when Johnson & Johnson initially reported the completion of its acquisition of Pfizer's Consumer Healthcare business on December 21, 2006. This amended filing ensures investors have the complete financial picture of the transaction.

The acquisition of Pfizer's Consumer Healthcare business was completed for a total purchase price of $16.6 billion in cash.

This filing includes audited combined financial statements for Pfizer Consumer Healthcare for the years ended December 31, 2005, and December 31, 2004. It also includes unaudited combined financial statements for the nine months ended October 1, 2006, and October 2, 2005. Additionally, unaudited condensed combined pro forma financial information for Johnson & Johnson and its subsidiaries for the fiscal years ended December 31, 2006, and January 1, 2006, is provided.

Johnson & Johnson completed the acquisition of Pfizer's Consumer Healthcare business on December 20, 2006.